Brain glycogen is the largest glucose storage form in the central nervous system (CNS) and is increasingly being recognized as an important factor in brain energy metabolism (1, 2) . For example, its concentration exceeds that of brain glucose by severalfold, and depletion of glycogen significantly affects neuronal survival (3) . It has been reported that brain glycogen may be higher than previously thought (4 -6) , which may be explained by the fact that brain glycogen is a highly labile metabolite and requires a highly sensitive and accurate method for its biochemical measurement.
We recently developed a localized 13 C MRS method to quantify the 13 C brain glycogen signal. In previous studies brain glycogen metabolism was assessed in vivo with 13 Clabeling to enhance sensitivity (7, 8) . To date, in vivo 13 C MRS is the only method available to assess brain glycogen content and metabolism noninvasively. In vivo brain glycogen metabolism studies using 13 C MRS suggested that glycogen plays an important role as an emergency supply of energy during limited glucose transport that occurs in acute hypoglycemia (9) . The observed supercompensation of brain glycogen following hypoglycemia suggests a profound effect of acute hypoglycemia on brain glycogen metabolism and content, which may affect glucose-sensing and may explain in part the defective counterregulation observed after a single episode of insulin-induced hypoglycemia (1) . The 13 C MRS method for the localized measurement of brain glycogen metabolism and content was expanded to in vivo human studies (10) .
In liver, muscle, and heart, a variable proportion of total glycogen has been reported to exist in a low-molecularweight form, namely proglycogen (ϳ400 kDa), and in the form of macroglycogen (ϳ10 7 Da) (11) . Therefore, the brain glycogen signal is likely to have complex NMR relaxation properties (12) that can affect the reliability of its measurement in vivo, even though the majority of glycogen, if not all, can be detected by 13 C NMR spectroscopy in the heart (13), muscle (14) , and liver (15, 16) .
Therefore, in vivo localized 13 C MRS measurement of brain glycogen should represent the total 13 C glycogen in the brain. The aim of this study was to validate in vivo 13 C NMR measurements of brain glycogen C1 by comparison with a standard biochemical assay.
MATERIALS AND METHODS

Animal Preparation
All in vivo studies were performed according to the guidelines of the University of Minnesota for the care and use of laboratory animals, and were approved by the Institutional Animal Care and Use Committee (IACUC). Eleven male Sprague-Dawley rats (150 -175 g; Harlan Inc., WI, USA) were obtained 2 weeks before the studies. On the day of the experiment, the rats (252 Ϯ 2 g, mean Ϯ SD) had been subjected to a 16-hr overnight fasting period. They were prepared under 2% isoflurane anesthesia in a 2:1 mixture of nitrous oxide (N 2 O) and oxygen (O 2 ), and ventilated with a pressure-driven ventilator (Kent Scientific Inc., CT, USA). Both femoral arteries were catheterized for blood sampling (plasma glucose and blood gas) and both femoral veins were catheterized for administration of test substances (␣-chloralose, insulin and [1-
13 C]-D-glucose). Once vascular access was secured, anesthesia was switched to ␣-chloralose (Sigma-Aldrich Inc., MO, USA) with a 40-mg/kg bolus followed by a ϳ26.7-mg/kg/hr continuous i.v. infusion.
Shortly thereafter, insulin (1 U/mL, Humulin® R; Lilly Inc., IN, USA) was administered to reach the target hypoglycemic condition of plasma glucose Ͻ 2 mM. Simultaneously, a 20% w/v solution of [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] C]-D-glucose (Isotec Inc., OH, USA; CIL Inc., MA, USA) was infused at a rate ranging from 0.1 to 1 mL/hr to avoid plasma glucose falling below 1 mM. Immediately after ϳ2 hr of acute hypoglycemia, a 13 C glucose bolus followed by an adjustable continuous glucose infusion rate was used to establish mild hyperglycemia at a target concentration of ϳ11 mM. During the second hour of this hyperglycemia recovery period, the animals were stereotaxically fixed with ear bars in an in-house-made holder, as described previously (8) , and placed in the magnet.
Throughout the entire study period, the animals' body temperature was maintained at 37°C by warm water circulation (RTE-101 bath circulator; Thermo NESLAB, NH, USA) based on feedback from a rectal temperature probe (Cole Palmer Inc., IL, USA.). During the hypoglycemic study, arterial blood was withdrawn at 5-10-min intervals and spun down to obtain plasma glucose levels with an Analox GM7 analyzer (Analox Instruments, MA, USA). Concurrently, physiological parameters (i.e., PaO 2 , PaCO 2 and pH) were maintained based on measurements of withdrawn arterial blood with a blood gas analyzer (Rapidlab 248; Bayer Corp., UK) at ϳ30-min intervals, which were adapted to be the sampling intervals during hyperglycemia. All in vivo MRS studies were performed in a horizontal 9.4-T/31-cm magnet (Magnex Scientific, UK) with an 11-cm-diameter gradient coil capable of switching to 300 mT/m in 500 s, interfaced with an INOVA console (Varian Inc., CA, USA). A quadrature 1 H radiofrequency (RF) 14-mm-diameter coil and a linear polarized, threeturn 11-mm-diameter 13 C RF coil (17, 18) were used as the transceiver. A sphere containing 99% 13 C-enriched formic acid (FA) was located at the center of the 13 C coil as an external reference, and the coil was placed on the animal's head as described previously (7, 8, 18) . Fast Automatic Shimming Technique by Mapping Along Projections (FASTMAP) shimming with echo-planar imaging (EPI) readout (19) was applied to adjust B 0 field homogeneity in a nominal ϳ440 L volume of interest. The Single-shot Inversion Recovery based Non-Echo (SIRENE) sequence (7) was applied for 3D localization with optimized outer volume suppression (e.g., for glycogen, the inversion time (TI) was 0.11 s) (7, 8, 18) to ensure elimination of signals from noncerebral tissue, and bilevel WALTZ-16 RF pulses were applied at the water frequency for generation of a nuclear Overhauser effect (NOE) and for decoupling during acquisition (7) .
Twelve 64-scan localized 13 C MR spectra (repetition time (TR) ϭ 1 s) acquired during the last half hour of hyperglycemia recovery were summed, apodized by 20-Hz exponential line-broadening, zero-filled, and Fourier transformed. The glycogen C1 signal intensity (I Glyc invivo ) was fitted using built-in spectrometer software (Varian Inc.) with a fixed linewidth obtained from the spectrum obtained by summing all acquisitions during the entire experiment. I Glyc invivo was quantified using the external reference method, based on the measurement of the signal from a phantom containing 400 mM of natural abundance oyster glycogen (Sigma-Aldrich Inc.) (I Glyc ref ) under identical experimental conditions as for the in vivo studies (8) , including temperature. The glycogen C1 signal intensity in the phantom was slightly temperature-dependent, as judged from separate measurements at 21°C, 37°C, and 55°C using the same settings as for the in vivo studies described above except that no localization, no decoupling, and TR ϭ 20 s were used. The in vitro oyster glycogen C1 signal intensity at ambient room temperature (21°C) was reduced by ϳ16% compared to that at 37°C, which was ϳ8% lower than that at 55°C. In vivo 13 , and NOE/T 1 effects assessed from the fully relaxed glycogen signal as in previous studies (7, 8) :
[1]
The glycogen solution was 400 mM natural abundance (1.1%) oyster glycogen, and 1 mM ϳ 1 mol/g was assumed.
Enzymatic Determination of In Vitro Glycogen Concentration
Shortly after completion of the in vivo 13 C MRS measurement (Ͻ10 min), the animals were carefully killed with the use of a focused microwave fixation device (Gerling Applied Electronics, Modesta, CA) at 4 kW within 1.4 s (6). The brain (excluding cerebellum) was removed from the skull and stored in a -80°C freezer (Thermo Forma, OH, USA) for further processing.
Within 8 weeks, the frozen brains were pulverized under liquid N 2 using a mortar and a pestle. The well-mixed brain powder was separated into two ϳ200-mg samples to determine brain glycogen content using a standard biochemical assay (20) , as follows: Briefly, 500 L of 0.03 M HCl were added to each sample, homogenized well (25-kHz ultrasonic processor, Cole Parmer Inc.), and heated for 45 min at 80ϳ90°C in a water bath. From each sample, two identical 200-L aliquots were taken and treated in exactly the same way, except that 5 L of 5-mM sodium acetate was added to the "minus" sample (to yield tissue glucose concentration), and 5 L of amyloglucosidase (Roche Diagnostics Corp., IN, USA) solution was added to the "plus" sample (to yield total tissue glucosyl concentration). The samples were pH-adjusted to 5 and incubated for ϳ2 hr at 37°C in a reciprocal water-bath shaker (New Brunswick Scientific Co., Inc., NJ, USA).
Glucose levels were determined at room temperature and the readouts were ensured to be in the linear range of the analyzer (Analox GM7 analyzer, see above). The glu- [4] In vitro 13 C glycogen ([ 13 C-Glyc] invitro ) was calculated from the product of [Glyc] invitro and IE Glyc .
Statistics
The experimental errors of each in vivo 13 C glycogen measurement were determined from all the arrayed spectra used for final in vivo 13 C glycogen quantification, as described in Materials and Methods. The errors of the glycogen assay were determined by two parallel measurements, as described above. The rest of the errors in the present studies were calculated according to the law of propagation of measurement errors, with exception of the FA signal (Eq. [1] ), glycogen phantom study, and 1 H MRS determination of IE (all of which were assumed negligible). All data are represented as the mean Ϯ SD. Significance was determined by means of a two-tailed Student's t-test, and a P-value Ͻ 0.05 was considered statistically significant.
RESULTS
To achieve a high glycogen tissue content and a high degree of 13 C labeling of the glucose residues of brain glycogen, supercompensation resulting from insulin-induced acute hypoglycemia (21) was adopted in the present studies. All 11 rats were intravenously administered 38 Ϯ 5 U/kg of insulin, which resulted in acute insulin-induced hypoglycemia (plasma glucose ϭ 1.60 Ϯ 0.03 mM) for 2.0 Ϯ 0.1 hr, followed by hyperglycemic recovery (plasma glucose ϭ 12.0 Ϯ 1.3 mM) for 12.4 Ϯ 1.2 hr. Throughout the in vivo experiments the animals were maintained under physiological conditions (i.e., pH ϭ 7.39 Ϯ 0.02, pCO 2 ϭ 39.6 Ϯ 1.9 mmHg, pO 2 ϭ 154.4 Ϯ 14.2 mmHg, and temperature ϭ 37.1 Ϯ 0.1°C).
The arrayed spectra acquired for the determination of in vivo 13 C glycogen were visually verified to be close to steady state. The brain [1- 13 C]-glycogen signal was typically detected with a high SNR (Fig. 1) . The external reference quantification of in vivo 13 C glycogen signal indicated a modest temperature dependence of glycogen C1 signals in the oyster glycogen solution (see Materials and Methods) and thus was applied at 37°C. The in vivo 13 C glycogen concentration ranged from 2.7 to 10.5 mol/g wet weight, and the estimated average error of the NMR measurements was SD NMR ϭ 1.3 mol/g and Ͻ2.1 mol/g.
In vitro glycogen content was determined on the same brains as measured by in vivo NMR, resulting in total brain glycogen concentrations ranging from 5.9 to 15.6 mol/g FIG. 1 . In vivo localized 13 C NMR spectra of brain glucose and glycogen. The spectrum shown was obtained right at the end of the in vivo 13 C MRS study and is the sum of 768 scans from 12 64-scan interleaved spectra from a 440-L volume. The brain glycogen C1 signal is well above the noise level (SNR). Processing consisted of 20 Hz exponential multiplication, zero-filling, FFT, and phase correction. The spectrum is shown with a linear baseline correction.
wet weight. In vitro 13 C enrichment of glucose was based on 1 H MRS measurements at 14.1-T with well-resolved 12 C1-␣ glucose proton signals at 5.21 ppm and 13 C1-␣ glucose proton signals at 5.07 and 5.35 ppm (Fig. 2) . From 90% of IE free and 81% of IE dig , an average 77% IE of glycogen (IE Glyc ) was calculated based on Eq. [4] . Multiplying the total enzymatic glycogen content ([Glyc] invitro ) with the IE of glycogen (IE Glyc ) resulted in in vitro 1-13 C glycogen concentrations ranging from 4.0 to 13.6 mol/g with an average SD invitro of 0.6 mol/g and Ͻ2.3 mol/g.
When the in vivo 13 C glycogen concentration was plotted as a function of in vitro 13 C glycogen content (Fig. 3) , a highly linear correlation with a slope of 0.75 Ϯ 0.07, mean Ϯ SE (solid line) was obtained. All but two of the measured data points were within experimental error of the identity line (dashed line).
DISCUSSION
In this study we used a "gold standard" method (i.e., amyloglucosidase assay of glycogen) to directly compare the quantification of brain [1- 13 C]-glycogen to that obtained with in vivo localized 13 C MRS in the same brain. The correlation was high over a wide range of 13 C glycogen concentrations and close to identity within experimental errors, as shown in Fig. 3 .
The low 13 C MRS sensitivity was compensated was compensated by increasing the 13 C content of brain glycogen by inducing supercompensation as in previous studies (9) , which was adapted in this study by first depleting brain glycogen using insulin-induced moderate hypoglycemia and then repleting it using 13 C glucose infusions. The ensuing supercompensation was observed in the present study even after ϳ12 hr of recovery both by in vivo NMR and by biochemical methods, with an average post-hypoglycemic 13 C glycogen level of 6.8 Ϯ 3.3 mol/g, confirming qualitatively the findings of previous reports (9) .
A higher brain 13 C glycogen content led to a high SNR of in vivo NMR signals (Fig. 1) and resulted in an excellent estimation of in vivo 13 C glycogen concentrations with only 768 scans, which is far fewer scans than used in previous muscle glycogen measurements (14) . This was evidenced by SD NMR ϭ 1.3 mol/g in absolute terms, which is comparable to the error (in terms of 13 C concentration) observed in previous validation studies performed in rabbit muscle (14) and liver (15) , despite the fact that brain glycogen was severalfold less concentrated. This implies increases in sensitivity ascribed to improvements in B 0 , RF coil design, and localization methodology. We minimized the potential effect of the observed temperature dependence of glycogen signal (ϳ10% signal intensity loss) on the accuracy of the in vivo quantification by performing the external reference at body temperature (i.e., 37°C).
In the present study, in vitro brain glycogen was determined in the same brain tissue, obtained immediately after the in vivo NMR measurement. Brain tissue was rapidly fixed within 1.4 s, as in previous studies by our group (20, 22) and others (6, 23, 24) , which minimized potential underestimation of the brain glycogen concentration due to its rapid postmortem degradation. In particular, the physiological conditions of the animals at the time of fixation were identical to those used when the NMR measurement was performed (data not shown). In vitro 1 H NMR spectra of glucose C1-␣ proton signals on processed post-assay samples at 14.1-T exhibited well-resolved proton signals (Fig. 2) , from which in vitro 13 C glycogen content was calculated. Despite the involved error propagation SD invitro was lower than SD NMR , especially at lower concentrations.
The errors of both in vivo 13 C glycogen signals and in vitro 13 C glycogen contents may include additional factors beyond measurement errors, such as variations in plasma glucose. Previous studies have shown that steady-state plasma glucose has a linear relationship with brain glucose (18, 20, (25) (26) (27) . Given the effect of brain glucose on brain glycogen content (unpublished data; also see Refs. 9 and 22 and references therein), it is possible that variations in the plasma glucose levels can affect brain 13 C glycogen levels. In this study, the maximum difference of plasma glucose did not exceed 3.5 mM. However, if we exclude data points with a plasma glucose difference higher than 1.8 mM before and after the arrayed spectra acquisition, the slope of comparison between the two methods was 0.72 with R ϭ 0.78, which is not significantly different (P Ͼ 0.05) and therefore does not affect the conclusions of the present study.
Considering the overall variation of in vivo 13 C glycogen quantification (SD NMR ϭ 1.3 mol/g) and one specific data point with a standard deviation (SD) of SD invitro ϭ 2.3 mol/g, all points but one were within the identity line (dashed line in Fig. 3 ). The excellent agreement between the two methods is further supported by plotting the differences of the two methods against the mean brain 13 C glycogen content (Fig. 4) , in which only two differences fall outside Ϯ 2 SD (SD ϭ 2.1 mol/g of the difference, shaded area in Fig. 4 ) of the line of perfect agreement (solid line), the rest being within Ϯ 2 SD NMR (SD NMR ϭ 1.3 mol/g).
It has been reported that the T 2 of glycogen is multiexponential (12) and that the complex structure of glycogen may lead to significant fractions of the glycogen C1 resonance having a substantially larger linewidth. The fact that the slope was slightly below 1 (Fig. 3) could signify a small overall contribution of broad resonances to the signal that was not accounted for.
The aforementioned two forms of glycogen-proglycogen and macroglycogen-appear to behave differently in glycogen metabolism. For example, it has been reported that proglycogen is not be actively involved in glycogen metabolism (28) and therefore is not likely to be labeled by 13 C label administration. Although in the present study the majority of brain glycogen was depleted by the introduction of acute hypoglycemia, in principle it is possible that some proglycogen was not depleted and completely labeled due to longer turnover times. This could explain the small but significant reduction in IE of glycogen 77%, compared to tissue glucose 90%. This is consistent with a previous 13 C MRS study on cardiac glycogen (13) . Whatever the origin of the minor discrepancy between the in vivo and biochemical measurements, its consequence must be minimal in investigations that show large changes in brain glycogen C1 content, as previously reported (9) .
We conclude that NMR measurements of brain glycogen C1 overall reliably reflect the biochemically measured 13 C glycogen content. Therefore, in vivo 13 C MRS in conjunction with 13 C glucose infusion is an accurate and precise method for assessing in vivo brain glycogen metabolism . FIG. 4 . Difference between the two methods plotted against the mean brain 13 C glycogen concentration. Each closed diamond represents the difference between the two methods plotted against the corresponding mean from the two methods. The dotted line indicates the average difference (-1.7 mol/g), and the dashed lines indicate the average Ϯ 2 SD (SD ϭ 2.1 mol/g of the difference). The shaded area covers the 95% confidence interval of the measurements assuming perfect agreement of the methods (i.e., 0 Ϯ 2 SD).
